A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
Stanford is now accepting new patients for this trial.
- Chitra Venkatasubramanian, MBBS, MD, MSc.
- Neil Schwartz, MD, PhD
- Anna Finley Caulfield, MD
- Maarten Lansberg, MD, PhD
- Marion S. Buckwalter, MD, PhD
- drug : Desmoteplase
- drug : Placebo
Phase: Phase 3
Ages Eligible For Study:
- Diagnosis of acute ischemic stroke - Informed consent - Age between 18 and 85 years - Treatment can be initiated within 3 to 9 hours after the onset of stroke symptoms - NIHSS Score of 4 to 24 - Vessel occlusion or high-grade stenosis on MRI or CTA in proximal cerebral arteries